Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ianalumab in diffuse cutaneous systemic sclerosis
CTR20244052Phase 2Active
- Sponsor
- Novartis
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ianalumab in systemic sclerosis (SSc), sponsored by Novartis. Started Feb 2025; status: active.
02
Drugs
ianalumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on CTR20244052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244052.